Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Liraglutide

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

Novo Nordisk · Phase 2 · Completed · Enrollment 834

NCT03235050

ArmNauseaVomitingDiarrheaDiscontinuationDeaths
MEDI0382 low dose + Metforminn/rn/rn/rn/rn/r
MEDI0382 mid dose + Metforminn/rn/rn/rn/rn/r
MEDI0382 high dose + Metforminn/rn/rn/rn/rn/r
Placebo + Metformin12 participants5 participants10 participantsn/r0
Liraglutide + Metformin17 participants3 participants4 participantsn/r0
MEDI0382 100 mcg23 participants10 participants13 participantsn/r0
MEDI0382 200 mcg85 participants51 participants49 participantsn/r2
MEDI0382 300 mcg105 participants43 participants28 participantsn/r1

A count stays a count. This page does not turn a count into a percent.